Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

DDRAsTic

Financiado

Targeting DNA Damage Response and Metabolism for Precision Medicine in Rheumatoi...

Targeting DNA Damage Response and Metabolism for Precision Medicine in Rheumatoid Arthritis Rheumatoid arthritis (RA) is an autoimmune disease that affects millions of people worldwide, and its negative health burden is accelerating in the ageing population. Despite many available treatments, up to 40% of RA patients do... ver más

30/09/2026

223K€

Presupuesto del proyecto: 223K€

Líder del proyecto

KAROLINSKA INSTITUTET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-03-19

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

HORIZON-MSCA-2023-PF-01-01: MSCA Postdoctoral Fellowships 2023

I+D

Cerrada hace 1 año

0% 100%

1 Participantes

222.73K€ | Lider

Proyectos interesantes

BTCURE BeTheCuRE 39M€ Cerrado

SAF2011-27261 ANALISIS DE LA EXPRESION DIFERENCIAL Y DEL FOSFOPROTEOMA EN... 145K€ Cerrado

PCIN-2017-093 ANTICUERPOS ANTI-FARMACOS Y DETECCION MOLECULAR DE FARMACOS... 121K€ Cerrado

RTI2018-094120-B-I00 NUEVOS ENFOQUES BASADOS EN PEPTIDOS SINTETICOS PARA EL DIAGN... 121K€ Cerrado

EUIN2015-62625 RED DE RE-CLASIFICACION MOLECULAR DE LAS ENFERMEDADES AUTOIN... 25K€ Cerrado

METHYLOMIC DNA methylation markers to predict treatment success of biol... 9M€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 30 meses Fecha Inicio: 2024-03-19
Fecha Fin: 2026-09-30

Líder del proyecto

KAROLINSKA INSTITUTET

TRL 4-5

Presupuesto del proyecto 223K€

Descripción del proyecto Rheumatoid arthritis (RA) is an autoimmune disease that affects millions of people worldwide, and its negative health burden is accelerating in the ageing population. Despite many available treatments, up to 40% of RA patients do not respond sufficiently to current therapies and the needs for a precision medicine approach and new treatments are pressing. The complexity of RA and unselective mechanisms of action of existing drugs are challenges. Current treatments also have unintended adverse effects because they affect healthy cell types in the body. The proposed project DDRAsTic focuses on a particular enzyme called MTHFD2, which plays a crucial role in the metabolism of folate and DNA damage response of activated T cells. Recent research and preliminary data, suggest that MTHFD2 is overactive in RA patients. DDRAsTic aims to address the hyperactive T-cell responses at the core of RA by targeting MTHFD2 with novel inhibitors that spare essential components, thereby minimizing the risk of toxicity and adverse effects. In parallel, DDRAsTic seeks to understand the underlying reasons for the limited efficacy of current RA treatments and explore potential biomarkers that can predict how patients will respond to standard therapies, with a specific focus on understanding the involvement of MTHFD2. The aim is to introduce a precision medicine approach in RA and identify a novel treatment. To achieve this, DDRAsTic adopts a multidisciplinary approach and uses patient-derived specimens, RA animal models and bioinformatics analysis from large cohorts of RA patients to undergo advanced imaging, cellular and molecular techniques. Overall, these analyses aim to provide insights into MTHFD2's regulatory role in abnormal immune responses and advance RA treatment by introducing precision medicine approaches and overcoming treatment toxicity.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores